Advances in Adjuvant Hormonal Therapy for Postmenopausal Women
- 10 March 2005
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (8) , 1751-1759
- https://doi.org/10.1200/jco.2005.11.038
Abstract
No abstract availableThis publication has 69 references indexed in Scilit:
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- The effect of anastrozole (Arimidex™) on serum lipids — a randomized comparison of Anastrozole (AN) vs Tamoxifen (TAM) in Postmenopausal women with Advanced Breast CancerEuropean Journal Of Cancer, 2001
- Effect of letrozole on the lipid profile in postmenopausal women with breast cancerEuropean Journal Of Cancer, 2001
- AnastrozoleDrugs & Aging, 1998
- LetrozoleDrugs, 1998
- A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *European Journal Of Cancer, 1996
- ON THE TREATMENT OF INOPERABLE CASES OF CARCINOMA OF THE MAMMA: SUGGESTIONS FOR A NEW METHOD OF TREATMENT, WITH ILLUSTRATIVE CASES.1The Lancet, 1896